Genetic disruption of EPAS1, which encodes HIF2α, with RNAi or CRISPR-based gene editing impairs the fitness of pVHL-defective ccRCC lines in cellular competition assays, suggesting that HIF2α has both cell-autonomous and nonautonomous effects on ccRCC (20–24). This evidence concerns the gene EPAS1 and nonpapillary renal cell carcinoma.